Rein Therapeutics, Inc. Common Stock RNTX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $0— | $0— | $0— | $0— | $0— | ||
| $3.07M+0.6% | $2M-39.8% | $1.68M-54.8% | $4.29M+14.7% | $3.05M-11.8% | ||
| $2.16M-15.6% | $1.96M-20.9% | $3.81M+62.2% | $2.58M-51.3% | $2.56M-31.7% | ||
| $5.23M-6.8% | $32.66M-23.7% | $5.49M-9.5% | $6.87M-24.0% | $5.61M-22.2% | ||
| -$5.23M+6.8% | -$32.66M+23.7% | -$5.49M+9.5% | -$6.87M+24.0% | -$5.61M+22.2% | ||
| -$608K-663% | —— | -$89K-140% | $49K-49.5% | $108K+17.4% | ||
| —— | -$178K+53.9% | -$178K+53.9% | -$178K+53.9% | -$178K+53.9% | ||
| -$5.84M-6.1% | -$31.97M+22.0% | -$5.58M+4.5% | -$6.82M+23.7% | -$5.5M+22.7% | ||
| -$0.19+24.0% | -$1.22+44.5% | -$0.21+22.2% | -$0.28+37.8% | -$0.25+70.9% | ||
| -$5.23M+6.8% | -$32.66M+23.7% | -$5.49M+9.5% | -$6.87M+24.0% | -$5.61M+22.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Rein Therapeutics, Inc. Common Stock profitable?
- Rein Therapeutics, Inc. Common Stock is not currently profitable: it reported a net loss of $50.2M over the trailing twelve months.
- What is Rein Therapeutics, Inc. Common Stock's earnings per share?
- Rein Therapeutics, Inc. Common Stock's diluted EPS over the trailing twelve months is $-1.90.
- Where does Rein Therapeutics, Inc. Common Stock's income statement data come from?
- Every line is extracted from Rein Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.